Insights

Innovative Technology Platform Eikon Therapeutics employs groundbreaking microscopy and molecular measurement technologies that enable highly sensitive drug target identification, creating opportunities to offer advanced imaging tools, analytical software, and laboratory automation solutions tailored to their unique research needs.

Expanding Clinical Pipeline With ongoing development of EIK1001 for non-small cell lung cancer and plans for pivotal trials, there is a strong demand for clinical trial services, contract research organizations, and regulatory consulting to support their accelerated drug development efforts.

Significant Investment Focus Backed by notable funding including a $351M Series D round from Soros Capital, Eikon is poised for rapid growth, providing opportunities for sales in cutting-edge biotech equipment, service partnerships, and collaborations with firms supporting high-content data analysis.

Leadership and Talent Expansion Recent hiring of senior executives and board members indicates a focus on strategic growth and operational scaling, creating opportunities to engage with executive recruitment services, leadership development resources, and corporate governance solutions.

Market Positioning As a biotechnology firm positioned between research and clinical development with a focus on novel therapies and high-tech discovery platforms, Eikon presents a prime opportunity for sales of specialized lab instruments, data management systems, and AI-driven analytics tailored for advanced biotech research environments.

Eikon Therapeutics Tech Stack

Eikon Therapeutics uses 8 technology products and services including GDPR, Cloudflare, Selenium, and more. Explore Eikon Therapeutics's tech stack below.

  • GDPR
    Certificates
  • Cloudflare
    Content Management System
  • Selenium
    Frameworks And Libraries
  • Vue.js
    Javascript Frameworks
  • Lenis
    Javascript Libraries
  • Planisware
    Project Management
  • Yoast SEO
    Search Engines
  • Autodesk
    Visualisation Software

Media & News

Eikon Therapeutics's Email Address Formats

Eikon Therapeutics uses at least 1 format(s):
Eikon Therapeutics Email FormatsExamplePercentage
LastF@eikontx.comDoeJ@eikontx.com
62%
First@eikontx.comJohn@eikontx.com
17%
First.Last@eikontx.comJohn.Doe@eikontx.com
12%
LF@eikontx.comDJ@eikontx.com
9%

Frequently Asked Questions

What is Eikon Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Eikon Therapeutics's official website is eikontx.com and has social profiles on LinkedInCrunchbase.

What is Eikon Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
Eikon Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Eikon Therapeutics have currently?

Minus sign iconPlus sign icon
As of December 2025, Eikon Therapeutics has approximately 385 employees across 4 continents, including North AmericaEuropeAfrica. Key team members include Chief Business Officer & General Counsel: B. T.Chief Operating Officer: M. K.Chief People Officer: B. H.. Explore Eikon Therapeutics's employee directory with LeadIQ.

What industry does Eikon Therapeutics belong to?

Minus sign iconPlus sign icon
Eikon Therapeutics operates in the Biotechnology Research industry.

What technology does Eikon Therapeutics use?

Minus sign iconPlus sign icon
Eikon Therapeutics's tech stack includes GDPRCloudflareSeleniumVue.jsLenisPlaniswareYoast SEOAutodesk.

What is Eikon Therapeutics's email format?

Minus sign iconPlus sign icon
Eikon Therapeutics's email format typically follows the pattern of LastF@eikontx.com. Find more Eikon Therapeutics email formats with LeadIQ.

How much funding has Eikon Therapeutics raised to date?

Minus sign iconPlus sign icon
As of December 2025, Eikon Therapeutics has raised $351M in funding. The last funding round occurred on Feb 26, 2025 for $351M.

When was Eikon Therapeutics founded?

Minus sign iconPlus sign icon
Eikon Therapeutics was founded in 2019.

Eikon Therapeutics

Biotechnology ResearchCalifornia, United States201-500 Employees

Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the interface of biology, engineering and chemistry to discover novel treatments for life-threatening diseases. Eikon’s discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes which enable real time, molecular-resolution measurements of protein movement in living cells. 

By directly measuring the effects of chemical compounds on the behavior of protein molecules in a live cellular environment, Eikon’s landmark assays facilitate the highly sensitive identification of compound-protein interactions that could not be identified through traditional assays, thereby unlocking otherwise intractable classes of proteins as drug targets. Furthermore, the ability to directly visualize protein mechanisms in disease coupled with the extraordinarily high-powered high-content data sets generated by Eikon’s drug-screening technology enable an unprecedented opportunity to quantitatively explore novel biology in the living cell. These insights facilitate creation and application of data-driven hypotheses to the discovery of life-saving therapies. 

Eikon is seeking adventurous, passionate and creative team members eager to apply their talents to empower interdisciplinary scientific exploration, inaugurate a radical drug-discovery paradigm, and ultimately create novel medicines. To learn more about open positions, please visit:  https://www.eikontx.com/join-us/#open-positions

Section iconCompany Overview

SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2019
Employees
201-500

Section iconFunding & Financials

  • $351M

    Eikon Therapeutics has raised a total of $351M of funding over 5 rounds. Their latest funding round was raised on Feb 26, 2025 in the amount of $351M.

  • $100M$250M

    Eikon Therapeutics's revenue is estimated to be in the range of $100M$250M

Section iconFunding & Financials

  • $351M

    Eikon Therapeutics has raised a total of $351M of funding over 5 rounds. Their latest funding round was raised on Feb 26, 2025 in the amount of $351M.

  • $100M$250M

    Eikon Therapeutics's revenue is estimated to be in the range of $100M$250M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.